Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Amedisys ( (AMED) ) is now available.
On July 29, 2025, Amedisys reported its financial results for the second quarter of 2025, showing an increase in net service revenue to $621.9 million, up from $591.2 million in 2024. Despite merger-related expenses, the company’s adjusted EBITDA rose to $80.8 million, and adjusted net income per diluted share increased to $1.54. The company is in the process of merging with UnitedHealth Group and will not conduct a quarterly earnings call due to this pending merger. This financial performance highlights Amedisys’s resilience and growth amidst merger activities, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AMED) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Amedisys stock, see the AMED Stock Forecast page.
Spark’s Take on AMED Stock
According to Spark, TipRanks’ AI Analyst, AMED is a Outperform.
Amedisys demonstrates strong financial performance and effective strategic management, including a recent credit facility extension amid merger talks. However, the high P/E ratio indicates potential overvaluation, and technical indicators signal limited momentum. These factors combine to produce a reasonably strong overall stock score.
To see Spark’s full report on AMED stock, click here.
More about Amedisys
Amedisys, Inc. is a leading healthcare services company specializing in personalized home health, hospice, and high acuity care services. Founded in 1982 and headquartered in Baton Rouge, Louisiana, with an executive office in Nashville, Tennessee, Amedisys operates approximately 519 care centers across 38 states and the District of Columbia, employing around 19,000 people. The company partners with over 3,300 hospitals and 114,000 physicians nationwide to provide post-acute care to more than 499,000 patients annually.
Average Trading Volume: 400,729
Technical Sentiment Signal: Hold
Current Market Cap: $3.18B
For detailed information about AMED stock, go to TipRanks’ Stock Analysis page.